MiR-331-3p Links to Drug Resistance of Pancreatic Cancer Cells by Activating WNT/β-Catenin Signal Via ST7L
Overview
Oncology
Pharmacology
Authors
Affiliations
Background: Pancreatic cancer is an aggressive type of cancer with poor prognosis, short survival rate, and high mortality. Drug resistance is a major cause of treatment failure in the disease. MiR-331-3p has been reported to play an important role in several cancers. We previously showed that miR-331-3p is upregulated in pancreatic cancer and promotes pancreatic cancer cell proliferation and epithelial-to-mesenchymal transition-mediated metastasis by targeting ST7L. However, it is uncertain whether miR-331-3p is involved in drug resistance.
Methods: We investigated the relationship between miR-331-3p and pancreatic cancer drug resistance. As part of this, microRNA mimics or inhibitors were transfected into pancreatic cancer cells. Quantitative polymerase chain reaction was used to detect miR-331-3p expression, and flow cytometry was used to detect cell apoptosis. The Cell Counting Kit-8 assay was used to measure the IC50 values of gemcitabine in pancreatic cancer cells. The expression of multidrug resistance protein 1, multidrug resistance-related protein 1, breast cancer resistance protein, β-Catenin, c-Myc, Cyclin D1, Bcl-2, and Caspase-3 was evaluated by Western blotting.
Results: We confirmed that miR-331-3p is upregulated in gemcitabine-treated pancreatic cancer cells and plasma from chemotherapy patients. We also confirmed that miR-331-3p inhibition decreased drug resistance by regulating cell apoptosis and multidrug resistance protein 1, multidrug resistance-related protein 1, and breast cancer resistance protein expression in pancreatic cancer cells, whereas miR-331-3p overexpression had the opposite effect. We further demonstrated that miR-331-3p effects in drug resistance were partially reversed by ST7L overexpression. In addition, overexpression of miR-331-3p activated Wnt/β-catenin signaling in pancreatic cancer cells, and ST7L overexpression restored activation of Wnt/β-catenin signaling.
Conclusions: Taken together, our data demonstrate that miR-331-3p contributes to drug resistance by activating Wnt/β-catenin signaling via ST7L in pancreatic cancer cells. These data provide a theoretical basis for new targeted therapies in the future.
MicroRNAs in pancreatic cancer drug resistance: mechanisms and therapeutic potential.
Dong F, Zhou J, Wu Y, Gao Z, Li W, Song Z Front Cell Dev Biol. 2025; 12:1499111.
PMID: 39882259 PMC: 11774998. DOI: 10.3389/fcell.2024.1499111.
Tao P, Yan X, Li Y, Wang Z Reprod Sci. 2025; .
PMID: 39821799 DOI: 10.1007/s43032-024-01783-6.
and as potential prognostic and therapeutic targets for adrenocortical carcinoma.
Situ Y, Deng L, Huang Z, Jiang X, Zhao L, Zhang J Cancer Biol Ther. 2024; 25(1):2428469.
PMID: 39545598 PMC: 11572284. DOI: 10.1080/15384047.2024.2428469.
Meng C, Yang Y, Feng W, Ma P, Bai R J Orthop Surg Res. 2023; 18(1):892.
PMID: 37993925 PMC: 10666460. DOI: 10.1186/s13018-023-04338-8.
Noncoding RNAs: an emerging modulator of drug resistance in pancreatic cancer.
Wei L, Sun J, Wang X, Huang Y, Huang L, Han L Front Cell Dev Biol. 2023; 11:1226639.
PMID: 37560164 PMC: 10407809. DOI: 10.3389/fcell.2023.1226639.